The electronic cigarettes segment by product is estimated to lead the market growth during the forecast period.

According to a new market research study of “North America Smoking Cessation Aids Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Product, End User and Country.” The North America smoking cessation aids market is expected to reach US$ 25,126.27 million in 2028 from US$ 9,049.15 million in 2021; it is estimated to grow at a CAGR of 15.7% from 2021 to 2028. The report highlights trends prevailing in the North America smoking cessation aids market and the factors driving market along with those that act as hindrances. Key factors that are driving the growth of this market are rising addiction toward tobacco smoking and increasing number of campaigns to reduce smoking and tobacco dependence. However, steeping costs for development of nicotine replacement therapies are likely to restrain the market growth in the future years to some extent.

The smoking of tobacco is proven to be dangerous in all forms as it can lead to chronic health conditions, preventable diseases, deaths, and disabilities. According to the World Health Organization (WHO), smoking-related disorders result in about 435,000 deaths per year in the US, which equals to around 1 in 5 of the total deaths in the country. Therefore, prevalence of tobacco smoking is high across various countries in the North America that drives the growth of the smoking cessation aids market. The government and nongovernment organizations worldwide are coming forward and launching campaigns to provide awareness and undertake measures to curb the diseases caused due to smoking and tobacco consumption. The measures are taken to reduce the economic and health burden caused due to cigarette smoking in countries worldwide. For instance, every year on May 31st, the WHO along with its global partners celebrate World No Tobacco Day (WNTD) to spread education and awareness regarding the harmful and deadly effects of tobacco and second-hand smoke exposure. Initiatives undertaken on this day mainly aim to discourage the consumption of tobacco in any form and educate people regarding the availability of aids that assist in smoking cessation. The launch of anti-smoking campaigns is organized on global, national, and regional levels worldwide.  The governments of various countries have increased excise duties and taxes on tobacco-based cigarettes and cigars to reduce its affordability, thus consumption among common populace. In addition, numerous governments have legalized the use of e-cigarettes as a smoking cessation aid under licensed sales channels to prevent people from opting conventional cigarettes. Thus, the increasing efforts undertaken by governments as well as non-profit and nongovernment organizations to promote the use of smoking cessation aids and reduce the number of smoking populations boost the growth of the market.

The North America smoking cessation aids market, by product, is segmented into nicotine replacement therapy, drugs, electronic cigarettes, and others. Based on end user, the North America smoking cessation aids market is segmented into hospital pharmacies, online channel, retail pharmacies, and other end users. Geographically, the North America smoking cessation aids market can be sub-segmented into U.S. Mexico and Canada.

Pfizer Inc., GlaxoSmithKline plc., Dr. Reddy's Laboratories, Johnson and Johnson Services, Inc., Cipla Inc., Perrigo Company plc, Bausch Health Companies Inc., Glenmark, NJOY and Juul Labs are among the leading companies operating in the North America smoking cessation aids market.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com